The TAILOR-PCI trial showed a trend towards reduced ischemic events with genotype-guided therapy versus universal clopidogrel use, although it did not reach statistical significance for the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and recurrent ischemia 186 .
1
—
—